PF-05280602 Uses, Dosage, Side Effects and more

PF-05280602 is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).

Trade Name PF-05280602
Generic Marzeptacog alfa (activated)
Marzeptacog alfa (activated) Other Names Marzeptacog alfa (activated), PF-05280602
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Innovators Monograph


*** Taking medicines without doctor's advice can cause long-term problems.
Share